Blue Danube Systems Introduces BeamPlanner™ Optimization Software and Expands Leadership in FDD Massive MIMO Commercial Engagements
Blue Danube Systems, a provider of mobile wireless access solutions that significantly and cost-effectively increase network capacity and enhance quality of service, today announced the release of BeamPlanner™, a software platform used in conjunction with the company’s BeamCraft™ active antenna systems that enables wireless carriers to optimize RF patterns to improve cell capacity and coverage based on siting conditions and dynamic user distributions.
BeamPlanner maximizes the effectiveness of multi-site active antenna deployment with sophisticated network optimization intelligence by directing RF energy to where the traffic is while steering clear of interference from neighboring sites. In addition, BeamPlanner automates network-wide configuration, scheduling, and management of BeamCraft systems and integrates seamlessly with existing wireless carrier’s RF planning workflows to simplify design in today’s dynamic mobile world.
Blue Danube recently completed its third commercial trial and first outside North America with Telstra in Australia where BeamPlanner was first used at a customer site. The Telstra trials, conducted in the 1800 MHz FDD spectrum, further demonstrated BeamCraft’s capability to form and switch beams with high fidelity to enhance network performance through a combination of improved coverage, capacity and interference reduction. The company’s earlier trials in the PCS and AWS spectrum, which started a year ago, established the industry’s first Massive MIMO systems in FDD networks. With the latest demonstrations, BeamCraft is also the first Massive MIMO system to be implemented in three different FDD bands with multiple operators.
In addition to the new trial, the company also received its first revenue order from a North American customer for a multi-site BeamCraft FDD deployment where BeamPlanner will be instrumental as part of the planning process to deliver an optimized site solution. More trials are planned for Europe, Asia and Latin America later this year, and the company will be opening an office in Europe in October to support the growing number of customers and partners.
Blue Danube also announced today that John Shelnutt is joining as Vice President of Sales as the company expands its executive team after raising its first Series-C funding recently in a round led by Silver Lake Kraftwerk. John has a broad background in the telecommunications industry, most recently at Cisco as Vice President/GM of Cisco’s Mobility Domain global business and before that as Cisco’s senior executive leader for AT&T. Prior to Cisco, John was the Executive Vice President of Goodman Networks, a wireless network deployment and services company. After beginning his career at Nortel, he spent 12 years at Alcatel and then Alcatel-Lucent where he held leadership positions in the DSL and Mobility businesses.
“We continue to make strong progress with additional commercial trials and are very excited to have John Shelnutt join our team to drive our sales growth and expansion,” said Dr. Mark Pinto, CEO of Blue Danube. “We also welcome Adam Grosser from Silver Lake to Blue Danube’s Board of Directors. Together with our strong investors and partners, we are confident that we will accelerate volume deployments and expand our product development to build a comprehensive 5G portfolio to address multiple markets.”
For more information, please visit www.bluedanube.com.
About Blue Danube System
Blue Danube Systems provides mobile wireless communications solutions that significantly and cost-effectively expand network capacity to enhance quality of service. The company’s proprietary approach combines reliable hardware and intelligent software to enable a significant increase in capacity, utilizing existing infrastructure and today’s mobile devices. Blue Danube Systems is backed by investors including Sequoia Capital, Northgate and AT&T and has locations in Warren, NJ and Santa Clara, CA. Blue Danube Systems is listed among EE Times Silicon 60 and is a winner of FierceWireless Fierce 15 for 2016. For more information, please visit www.bluedanube.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme